Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

2004145 citationsJournal Article

Authors

rPAF-AH was well tolerated and not antigenic, but did not decrease 28-day all-cause mortality in patients with severe sepsis.

Good health and well-being

Published in: Critical Care Medicine

Volume 32, Issue 2, pp. 332-341

Field-Weighted Citation Impact: 9.61